EP Patent

EP2309980A1 — Ophthalmic compositions for treating pathologies of the posterior segment of the eye

Assigned to Sifi Industria Farmaceutica Italiana Soc · Expires 2011-04-20 · 15y expired

What this patent protects

New compositions for ophthalmic use for the prevention and therapy of pathologies of the posterior segment of the eye are described. Said compositions, characterized by the use of xanthan gum as active principle carrier, can be advantageously administered as liquid gel eye-drops …

USPTO Abstract

New compositions for ophthalmic use for the prevention and therapy of pathologies of the posterior segment of the eye are described. Said compositions, characterized by the use of xanthan gum as active principle carrier, can be advantageously administered as liquid gel eye-drops on the surface of the eye and optionally used in combination with other therapies for the treatment of the same pathologies.

Drugs covered by this patent

Patent Metadata

Patent number
EP2309980A1
Jurisdiction
EP
Classification
—
Expires
2011-04-20
Drug substance claim
No
Drug product claim
No
Assignee
Sifi Industria Farmaceutica Italiana Soc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.